Cantuzumab mertansine

Cantuzumab mertansine is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Immunogen Inc.

Mechanism of Action

Cantuzumab mertansine works by targeting the CanAg antigen, a protein found in many types of cancer cells, including colorectal cancer and pancreatic cancer. The drug is composed of a monoclonal antibody, cantuzumab, linked to a cytotoxic agent, mertansine. The antibody binds to the CanAg antigen on the surface of cancer cells, allowing the cytotoxic agent to enter and kill the cell.

Clinical Trials

Cantuzumab mertansine has been tested in several clinical trials. In a phase I trial, the drug showed some efficacy in patients with CanAg-positive tumors. However, in a phase II trial, the drug did not meet its primary endpoint of improving overall survival in patients with metastatic colorectal cancer.

Side Effects

Common side effects of cantuzumab mertansine include nausea, vomiting, and diarrhea. Serious side effects can include neutropenia, a condition characterized by low levels of neutrophils, a type of white blood cell.

Future Development

Despite the disappointing results of the phase II trial, research into cantuzumab mertansine continues. Scientists are exploring ways to increase the drug's efficacy, such as combining it with other treatments or modifying the antibody to better target cancer cells.

See Also

• Monoclonal antibodies in oncology
• Targeted therapy
• Immunotherapy

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian